• Title/Summary/Keyword: H3N8 EIV

Search Result 2, Processing Time 0.017 seconds

Inefficient Transmissibility of NS-Truncated H3N8 Equine Influenza Virus in Dogs

  • Na, Woonsung;Song, Manki;Yeom, Minjoo;Park, Nanuri;Kang, Bokyu;Moon, Hyoungjoon;Jeong, Dae-Gwin;Kim, Jeong-Ki;Song, Daesub
    • Journal of Microbiology and Biotechnology
    • /
    • v.25 no.3
    • /
    • pp.317-320
    • /
    • 2015
  • H3N8 equine influenza virus (EIV) causes respiratory diseases in the horse population, and it has been demonstrated that EIV can transmit into dogs owing to its availability on receptors of canine respiratory epithelial cells. Recently, we isolated H3N8 EIV from an EIV-vaccinated horse that showed symptoms of respiratory disease, and which has a partially truncated nonstructural gene (NS). However, it is not clear that the NS-truncated EIV has an ability to cross the host species barrier from horses to dogs as well. Here, we experimentally infected the NS-truncated H3N8 EIV into dogs, and monitored their clinical signs and viral load in respiratory organs to determine the virus's transmissibility.

Antibody responses after vaccination against equine influenza in Korea in 2016-2018 (2016년에서 2018년에 국내 말 인플루엔자 백신 접종 후 항체 양성률)

  • Cho, Min-Su;Lee, Ju-Yeon;Lee, Sang Kyu;Song, Jae Young;Lee, Jienny;Hyun, Bang-Hun;Cho, Soo-Dong;Ouh, In-Ohk
    • Korean Journal of Veterinary Research
    • /
    • v.59 no.3
    • /
    • pp.151-155
    • /
    • 2019
  • Equine influenza (EI) is the main cause of respiratory illness in equines across the globe and is caused by equine influenza A virus (EIV-A), which has impacted the equine industry internationally because of the marginal mortality and high morbidity. In the present study, the immune responses after equine influenza vaccination were evaluated in 4,144 horses in Korea using the hemagglutination inhibition (HI) assay. The equine influenza virus (EIV), A/equine/South Africa/4/03 (H3N8), was used as the antigen in the HI assay. The mean seropositive rates were 89.2% (97.4% in 2016, 77.6% in 2017, and 92.4% in 2018). This paper highlights the advances in understanding the effects of vaccines and control strategies for mitigating the emerging menace by EIV.